Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews describes the targeted therapy landscape in acute…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews explains how the treatment of acute myeloid…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews considers whether intensive chemotherapy should be used…
Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses how combination therapies are evolving to unmet needs…
Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses the unmet needs of the Phase 1/2 study…
Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone tells us about the design and outcomes of the…
Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma…
Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma…
Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI explains some common questions regarding PTEN patients. _________ Cleveland Clinic researchers have…
Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI clarifies genetic autism in PTEN patients. _______ Cleveland Clinic researchers have identified…
Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic speculates on the clinical impact of the TOURMALINE-AL1 study.
Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the side effects of the TOURMALINE-AL1 study presented at ASH 2019.
Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the outcomes of the TOURMALINE-AL1 study presented at ASH 2019.
Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the design of the TOURMALINE-AL1 study presented at ASH 2019.
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA differentiates between various anti-CD-38 monoclonal antibodies and…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the promising data on multiple myeloma…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of CAR-T cell therapy…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of human BCMA CAR-T…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses the…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers outlines the…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses how…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical…
Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical…
Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the implications of real-world…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the results and findings…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence)…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence)…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
Briggs Morrison, MD Chief Executive Officer of @Syndax discusses important details to note in this study. ___________ Syndax Pharmaceuticals, Inc.…
National Comprehensive Cancer Network to address HPV-related cancer prevention and treatment with World Cancer Day fundraiser and at upcoming NCCN…
United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin® (dinutuximab) Injection added to irinotecan…
Briggs Morrison, MD Chief Executive Officer of @Syndax answers how likely is this to translate into being beneficial for patients…
Moleculin Biotech, Inc., (Nasdaq:Â MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates…
Briggs Morrison, MD Chief Executive Officer of @Syndax discusses a preclinical study on the activity of menin-MLL inhibition for the…
– If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with…
Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different…
Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich answers commonly asked questions in pharmacogenomics and endocrine therapy in breast…
– Application Supported by Results of Pivotal HER2CLIMB Trial -Â – First Investigational Therapy in a Pivotal Trial to Include…
Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich discusses endocrine therapy in breast cancer.
Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals’ lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with…
Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type…
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer explains getting results down in oral paclitaxel: a Phase III clinical…
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer answers frequently asked questions on paclitaxel shown to be superior to…
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer on paclitaxel shown to be superior to IV paclitaxel on confirmed…
First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic…
– Improved clinical outcomes in advanced gastric/gastroesophageal junction cancer patients with DKK1-high tumors when treated with DKN-01 and anti PD-1…
Philadelphia, PA (January 27, 2020) – Oncoceutics announced that the National Brain Tumor Society (NBTS) has committed to providing more…
Today, the American Society of Hematology (ASH) released new clinical practice guidelines on Sickle Cell Disease (SCD)-Related Transfusion Support. These…
GRACE is very excited to bring to you our new program, Supportive Care in Cancer Treatment.Arjun Gupta, MD is the…
 First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, Accurate and Actionable Genomic Information to…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses what’s next in research for the TOUMRALINE-MM4 study. _________…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses safety concerns regarding the trial. _________ Read here:Â https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/ Â
The American Society of Hematology (ASH) is pleased to announce that Gabriela Hobbs, MD, of Massachusetts General Hospital, and Oluwatoyosi…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics explains how this is going to affect clinicians today and what clinicians should…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses whether they will be submitting to the FDA or not.
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers what data has come out of the trial? _________ Oncoceutics, Inc. announced…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine answers why ninlaro was compared to a placebo in TOURMALINE-MM4. Dr. Dimopoulous…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers how can we get access to this drug for glioblastoma? ___________ Oncoceutics,…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the design of the TOURMALINE-MM4 study and answers if the trail…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the phase 3 trial of ninlaro as first line maintenance therapy…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses what’s next in ONC201 in adult recurrent glioblastoma. __________ Oncoceutics, Inc. announced…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses the clinical efficacy of weekly ONC201 in adult recurrent glioblastoma. ________ Oncoceutics,…
Data to include early analyses of Stivarga® (regorafenib) across HCC, CRC and GI cancers, including Phase 1b data in combination…
In Roswell Park study, 42% of patients who received gabapentin for pain managementrequired no narcotics Most patients treated for head…
Thomas Powles, MD, MBBS @tompowles1 of @QMBCI discusses how the JAVELIN study affects clinicians and treatment today.
Thomas Powles, MD, MBBS @tompowles1 of @QMBCI answers common questions regarding the JAVELIN study including what happens to patients with…
Thomas Powles, MD, MBBS @tompowles1 of @QMBCI explains the phase III JAVELIN study in urothelial cancer.
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam…
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam…
Patrick Therasse, MD of Servier Group discusses Servier’s R&D efforts in oncology.
First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, Accurate and Actionable Genomic Information to Oncology…
Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center…
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the…
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the…
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the…
ACE1702 is a potential off-the-shelf cell therapy developed using Acepodia’s Antibody-Cell Conjugation technology Acepodia, a biotechnology company developing cancer immunotherapy…
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the…
Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial Clinical Data Presentation and…
More central line-associated blood infections and catheter malfunctions seen with PICCs A new study provides convincing evidence that the use…
Hans Hammers, MD of UT Southwestern Medical Center discusses the role of radiation in kidney cancer at the KCA 2019.
Source: https://www.spreaker.com/user/cancergrace/narjust-duma-md-introduces-cancer-myths- GRACE is excited to bring to you a new series on Cancer Myths in the Latin Community. Our…
GRACE is very excited to bring you more of our program on supportive care in cancer treatment.Arjun Gupta, MD, one…
Thank you all for joining us for our live stream today! If you have questions please feel free to email…
GRACE is excited to bring you new information in our Bladder Cancer Program. For this first video of 2019, Dr.…
GRACE is excited to bring to our Spanish speaking community information on Cancer Basics.Our friend and partner, Narjust (N.J.) Duma,…
Androgen Deprivation Therapy (ADT) for Men with Prostate Cancer GRACE is very excited to bring to more info from our…
GRACE is excited to bring you new information in our Bladder Cancer Program. For this video, Dr. Ramy Sedhom introduces…
Dr. Duma is an Assistant Professor and Thoracic Oncologist at @UWcarbone, University of Wisconsin Carbone Cancer Center, and Former Chief…
Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the…
·         At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS)…
Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the…
The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in…
– Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric…
Betty Hamilton, MD of @ClevelandClinic discusses the post-transplant work statue of young adult survivors of allogeneic hematopoietic cell transplant.
Abby Statler, MD of @ClevelandClinic answers if racial disparities in AML are associated with organ dysfunction.
Ajay K. Nooka, MD of @WinshipAtEmory discusses multiple myeloma disparities.
Robert Kreitman, MD of National Cancer Institute discusses Lumoxiti® phase III trial in patients with relapsed or refractory hairy cell…
Allison M. Winter, MD of @ClevelandClinic discusses comparative outcomes of relapsed follicular lymphoma patients treated with novel agents.
Hope Rugo, MD of @UCSFMedicine discusses the SOPHIA Study. _____________ MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering…
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of…
Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is…
Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is…
Jennifer Crozier, MD of @BaptistHealthSA discusses the FLEX real world data in early stage breast cancer.
William Audeh, MD of @Agendia discusses new data presented at SABCS demonstrating how genomic profiling benefits early stage breast cancer.
Jay Andersen, MD of Compass Oncology discusses the phase 3 KEYNOTE-522 trial was investigating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 immunotherapy, in…
Rafella Colombatti of University of Padova discusses the European perspective on sickle cell research.
Andrew Campbell, MD of Children’s National Hospital discusses the CASiRE study.
Peter Voorhees, MD of @LevineCancer discusses the depth of response to dara, lenalidomide, bortezomib, and dexamethasone (RVd) improves over time…
Timothy Illidge, MD, PhD of @OfficialUoM provides analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients…
Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with…
Chadi Nabhan, MD MBA of Aptitude Health discusses potential of biosimilars in treatment of blood cancer.
– Jazz to pay an upfront payment of $200 million to PharmaMar – Opportunity for Jazz to expand its oncology…
Shyamala Navada, MD of @MountSinaiNYC discusses the phase II study of oral rigosertib combined with azacitidine as first line therapy…
Jeff Sharman, MD of @TheUSONetwork discusses the phase III ELEVATE TN trial. _______ Read here:Â https://www.oncologytube.com/video/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukemia?channelName=Cancer-News
Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of…
Saro Armenian, DO of @cityofhope discusses the long term morbidity by survivors of AML treated with blood or marrow transplantation.
Professor Simon Rule of Plymouth University Medical School discusses long term outcomes with ibrutinib versus the prior regimen.
Roman Hajek, MD of University of Ostrava discusses MM patients remaining under represented in clinical trials based on standard laboratory…
Robert Rifkin, MD of @TheUSONetwork discusses the Lyra study.
Aziz Nazha, MD of @CleClinicMD discusses a personalized prediction model to risk stratify patients with AML.
Mohamed Zaki, MD of @abbvie discusses the phase 3 MURANO trial. ________ Read here:Â https://www.oncologytube.com/video/new-long-term-data-continues-to-demonstrate-progression-free-survival-and-overall-survival-benefits-with-venclexta-venclyxto-venetoclax-combination-in-patients-with-relapsed-refractory-ch-1
Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in…
Michael Wang, MD @michaelwangmd of @MDAndersonNews discusses KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with…
Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon Center for Blood Cancers discusses the phase 1 clinical study of bb21217.
Jan G. J. van de Winkel, Ph.D of @Genmab announces data to be presented at ASH 2019 including data from…
Jan Hillson, MD of @AlpineImmuneSci disucsses ALPN-101.
Steven Horwitz, MD of @sloan_kettering discusses the phase 2 PRIMO study. _______ Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company),…
Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial…
Aaron Gerds, MD of @CleClinicMD discusses the phase 2 study of luspatercept in patients with myelofibrosis-associated anemia
Aaron Gerds, MD of @CleClinicMD discusses the phase 2 study of luspatercept in patients with myelofibrosis-associated anemia
Fredrik Schjesvold, MD of Oslo University College addresses how this affects clinicians and what is next for research.
Fredrik Schjesvold, MD of Oslo University College disucsses the ICARIA-MM study.
Eric Fedyk, PhD of @TakedaPharma discusses the binding of CD38 therapeutics to red blood cells and platelets subverts depletion of…
Eunice Wang, MD of @RoswellPark discusses cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone (CLAG ± M) is highly effective…
Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib: what is next for research?
Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib.
Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients…
Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients…
David Gilham, MD of Celyad discusses a human NKG2D receptor-based CAR-T cell that potentially targets 80% of all cancers.
Christopher Yasenchak, MD of @TheUSONetwork discusses the phase 2 study of frontline brentuximab vedotin plus nivolumab.
Brian Hill, MD of Cleveland Clinic @ClevelandClinic discusses KTE-X19
Baiyan Wang, MD of Hospital of Xi’an Jiaotong University discusses the LEGEND-2 data.
Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multiple myeloma (MM) ineligible for transplant: updated analysis…
Alexey Danilov, MD of @OHSUNews discusses pharmacologic inhibition of SUMO-activating enzyme (SAE) with TAK-981 augments interferon signaling and regulates t…
– TAILORx Study Featured in William L. McGuire Memorial Lecture Award at 2019 San Antonio Breast Cancer Symposium® – New…
Jarrod Dalton, MD and David Zidar, MD of @CleClinicMD discuss lymphopenia associated with death due to heart disease, cancer and…
Agne Paner, MD of @RushMedical discusses updated data from the phase 2 HORIZON study. __________ Oncopeptides AB (Nasdaq Stockholm: ONCO)…
Jarrod Dalton, MD and David Zidar, MD of @CleClinicMD discuss lymphopenia associated with death due to heart disease, cancer and…
Jennifer Crombie, MD of @DanaFarber discusses a phase I study of duvelisib and venetoclax in patients with relapsed or refractory…
John Mascarenhas, MD of @MountSinaiNYC discusses MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi)
Nikhil Munshi of @DanaFarber discusses the phase I study evaluating interleukin-15 (IL-15) receptor agonist, NKTR-255 in MM and NHL.
Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Â Annual Meeting &…
Loui Madakamutil, PhD of Nektar Therapeutics discusses new preclinical Ddta for its IL-15 agonist, NKTR-255 at ASH 2019. ___________ Read…
MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing…
John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed…
Alexander Cohen, MBBS of Guys’ and St. Thomas’ NHS Foundation Trust answers the common questions asked about the safety and…
Alexander Cohen, MBBS of Guys’ and St. Thomas’ NHS Foundation Trust discusses the safety and effectiveness of apixaban, LMWH, and…
Thanos Zomas, MD of @TakedaOncology on brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): what’s next in…
Thanos Zomas, MD of @TakedaOncology discusses brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): 4-year update of…
Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer explains the SWAY study on sickle cell disease.
Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer discusses the unmet needs in sickle cell research.
Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer discusses the unmet needs in sickle cell research.
Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.: how this will affect clinicians and…
Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.
Rajat Bannerji, MD of @RutgersCancer provides an update on Phase I REGN1979. Â Â Â Â ash 2019, rutgers cancer,…
Dennis Cooper, MD of @RutgersCancer provides detail on his upcoming presentation at ASH about clinical data on REGN5458
Zsuzsanna Devecseri, MD of @SanofiGenzyme @sanofi discusses the pivotal Phase 3 ICARIA-MM trial of isatuximab, an investigational anti-CD38 monoclonal antibody,…
Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy…
Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy…
Mark Sellmyer, MD, PhD @sellmyerlab of @PennMedicine explains how CAR-T cell imaging markers will affect treatment and clinicians. ___________ Read…
Mark Sellmyer, Md, PhD @sellmyerlab of @PennMedicine answers how sensitive is this technology? ___________ Read here:Â https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php
Mark Sellmyer, MD, PhD sellmyerlab of @PennMedicine discusses to monitor cancer therapy, researchers tag CAR-T cells with imaging markers. ___________…
Dr. Susan Branford
Dr. Jorge Cortez
American doctor and cancer research scientist, Dr. William G. Kaelin, Jr. (Harvard University and Dana Farber Cancer Institute), along with…
Dr. Ekaterina Chelsheva
Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK…
Dr. Carla Bouqimpani
Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses…
– Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death…
NDA Submission for Accelerated Approval of Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma on Track for December 2019…
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more…
Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual…
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session…
The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a complete response (CR) at…
— The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) announced today a collaboration to expand access to LLS’s unique…
Joint FDA/ASH Led Initiative Highlights Importance of Using Patient Reported Outcomes and Biomarkers in Clinical Trials to Advance SCD Therapies The American Society…
Kymab, a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody-based therapeutics, today announced that abstracts describing two lead hematology programs,…
Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic…
Rachel Brake @rachael_brake of Takeda discusses results from the phase 3 ALTA-1L trial and answers commonly asked questions regarding the…
Atlanta Falcons and Atlanta United owner Arthur Blank’s gift is his second to Mount Sinai’s Department of Urology The Milton…
Meredith M. Regan,1 Michael B. Atkins,2 Thomas Powles,3 Lillian Werner,4 Charlene Mantia,5 Shuo Yang,6 Jennifer L. Johansen,6 Sumati Rao,6 Kyna…
Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro…
Nicholas Vogelzang, MD of Comprehensive Cancer Centers discusses his moderation of modern imaging technology.
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in…
Nicholas Vogelzang, MD of Comprehensive Cancer Centers discusses his moderation of modern imaging technology.
Today, ASH published new state-of-the art guidelines on the treatment of immune thrombocytopenia (ITP), a rare blood disorder characterized by…
Ulka Vaishampayan, MD of @karmanoscancer explains her moderation of management for clinical cases in kidney cancer.
James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer…
A new collaborative study led by Cleveland Clinic and University Hospitals has found that commonly used clinical indicators of immune…
Study results support development of LRIG1 as novel anti-cancer therapeutic Study is first to report that LRIG1 suppresses prostate cancer…
Oluwadamilola “Lola” Fayanju, MD @DrLolaFayanju of @DukeCancer answers nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy: how can…
Oluwadamilola “Lola” Fayanju, MD @DrLolaFayanju of @DukeCancer explains the nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy after…
Matt Campbell MD Assistant Professor GU Medical Oncology discusses The Argument for Front Line TKI based treatment for non-clear cell…
Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today announced that a review of recent work…
Viraj Master MD PhD FACS Professor Fray F. Marshall Chair in Urological Research Department of Urology Director of Integrative Oncology…
ALUNBRIG Reduced the Risk of Disease Progression or Death by 76% in Patients whose Disease Had Spread to the Brain,…
Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic…
Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic…
Marco Montillo, MD of @ospniguarda discusses the phase III DUO study. _________ https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-copiktratm-duvelisib-presentations-0 https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-copiktratm-duvelisib-presentations
Steven C. Campbell, MD, PhD Professor Surgery, Vice Chair, Program Director Section of Urologic Oncology, Department of Urology Glickman Urological…
Eytan Stein, MD of @sloan_kettering discusses the first patient dosed in phase 1/2 AUGMENT-101 trial of SNDX-5613 for the treatment…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Changing Paradigms…
Ritesh Kotecha, Erika Gedvilaite, Samuel Murray, Ashley Foster, Robert Motzer, Dana Tsui, Martin Voss Memorial Sloan Kettering Cancer Center presents…
Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma; supports phase 2 study –…
Gabriela Chiosis of @sloan_kettering explains the importance of paradigms for precision medicine in cancer therapy. __________ Read here:Â https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30427-1#%20
Gabriela Chiosis, of @sloan_kettering discusses paradigms for precision medicine in epichaperome cancer therapy. _______ Read here:Â https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30427-1#%20 Also Recomended: Synthesis of…
Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…
Daniel M. Rotroff, PhD of @CleClinicMD answers will this affect clinicians and treatment today on anti-PD-1/PD-L1 antibody immunotherapy. _________ Read…
Non-small-cell lung carcinoma (NSCLC) is an important area for the development and marketing of immuno-oncology (IO) drugs for most large…
Daniel M. Rotroff, PhD of @CleClinicMD answers commonly asked questions to anti-PD-1/PD-L1 antibody immunotherapy. _________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712
Daniel M. Rotroff, PhD of @CleClinicMD discusses the response to anti-PD-1/PD-L1 antibody immunotherapy. __________ Read here:Â https://ascopubs.org/doi/full/10.1200/JCO.19.01712
  Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new data will be presented on the efficacy…
Craig Slingluff, MD of @UVACancerCenter answers the study design and what is next for phase III data for a melanoma…
Philadelphia, PA (Nov. 19, 2019) – Oncoceutics, Inc. announced a publication in the journal Nature Communications demonstrating selective antagonism of…
Philadelphia, PA (November 13, 2019) – Oncoceutics, Inc. announced that results from the second and third cohort of the Phase…
Bryan Lewis, President KidneyCan discusses An Advocates Perspective to Increasing Funding Resources at the 18th International Kidney Cancer Symposium 2019,…
Craig Slingluff, MD of @UVACancerCenter discusses the phase III data for a melanoma vaccine, seviprotimut-L. ____________ — MAVIS Study Identifies…
Patients show improvements in blood vessels and physical ability after 8-week regimen — While exercise offers benefits for a wide range…
Christopher Wood, MD from MDAnderson holds a kidney cancer tumor board with real cases from the Kidney Cancer Association annual…
Hans Hammers MD, PhD presents Radiation to Prime the Immune System Filmed at the 18th International Kidney Cancer Symposium 2019,…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…